



14 May 2024

BIOXYNE AND CY BIOPHARMA FORGE STRATEGIC ALLIANCE TO DEVELOP NEW PSILOCYBIN THERAPIES IN AUSTRASIA

Bioxyne's 100% owned subsidiary, BLS WHOLESALERS PTY LTD, the only licensed Australian manufacturer of MDMA and psilocybin signs supply and collaboration agreement with CY Biopharma to develop ground breaking mental health and pain treatments for Australia and New Zealand.

Highlights

- **BLS is dedicated to developing commercially available psychedelic treatment options for patients with treatment-resistant depression and post-traumatic stress disorder in Australia, as well as commercial manufacturing for clinical research around the world.**
- **Cy Biopharma is committed to the research & development of natural and novel 5HTx agonists; prioritising serving patients with unmet medical needs in rare diseases by unlocking the therapeutic potential of psychedelics.**
- **Cy Biopharma AG's clinical development plans include both orphan and broader pain indications based on collaborations with regulators and top academic institutions like the Dana-Farber/Harvard Cancer Center to begin generating differentiating clinical data.**
- **Cy Biopharma will exclusively supply BLS with Psilocybe cubensis fungi for Australia and New Zealand.**

Australian life sciences and pharmaceutical Company **Bioxyne Limited** (ASX Code: BXN) (www.bioxyne.com) ("Bioxyne" or the "Company"), parent company of Breathe Life Sciences ("BLS") (www.bls.com.au) and **Cy Biopharma AG** of Switzerland (www.cybiopharma.com) is pleased to announce that the Company has entered into a commercial supply and collaboration agreement.

The opportunity is for BLS to manufacture and supply the Australian, New Zealand, US, and European clinical trials market with novel Psilocybin products; to develop proprietary formulations and drug delivery methods, and to supply to Australian patients via the authorized prescriber scheme.

Cy Biopharma will exclusively supply BLS with Psilocybe cubensis fungi for Australia and New Zealand.

Dr. Anton Hoos, CY Biopharma's CEO commented, *"There is a huge unmet medical need that 5HTx agonists may serve. Following the Australian government's pioneering decision to allow select experts to prescribe psilocybin, Cy Biopharma is pleased to enter into this partnership with BLS. Together we plan to build a reliable supply of pharmaceutical grade, naturally derived psilocybin for patients in Australia and New Zealand."*

In the coming 90 days BLS expects to manufacture the first Australian-made GMP Psilocybin capsules in Australia for commercial supply to approved clinical trials and patients, via the Authorized Prescriber Channel.

In this period BLS also expects to supply its first psilocybin products to research organisations in Australia and New Zealand.

Sam Watson, CEO of Bioxyne commented, *"Psychedelics are showing significant potential in the treatment of various mental health conditions; a beacon of hope for the large cohort of patients who do not respond to conventional treatment options. In Australia, 10.4% of people report experiencing symptoms of depression, and 33% of patients diagnosed with depression respond inadequately to current treatments within certain indications. Our goal is to help these patients get their lives back."*

In July 2023 the Therapeutic Goods Administration rescheduled Psilocybin and MDMA from Schedule 9 to Schedule 8 for the psychotherapy assisted treatment of PTSD and treatment resistant depression; while MDMA and psilocybin are not registered, the Authorized Prescriber Scheme will allow access to use by experienced psychiatrists under prescription.

The Company is not able to determine the financial contribution from the collaboration at this stage. The Company is committed to improving patient access and affordability.

This announcement has been approved for release by the Board of Bioxyne.

For further information contact:

Bioxyne & Breathe Life Sciences:

Sam Watson
Managing Director
Bioxyne Limited
hello@breathelifesciences.com

Jason Hine
Chief Operating Officer
Bioxyne Limited
info@bioxyne.com

Jane Morgan
Investor and Media Relations
Bioxyne Limited
jm@janemorganmanagement.com.au

About Bioxyne

Bioxyne Limited (ASX:BXN) is an Australian-headquartered international life sciences and pharmaceutical company (incorporated in 2000) with a focus on clinically effective health and wellness products, psychotropic and investigational medicines.

About Breathe Life Sciences (BLS)

Breathe Life Sciences (“BLS”) is a wholly owned subsidiary of Bioxyne Ltd (BXN:ASX) and licensed manufacturer, sponsor, importer and exporter of controlled substances (S3, S4, S8) in Australia.

BLS was founded in 2018 and has quickly expanded into a multinational business focused on alternative therapeutics and investigational medicines. Our corporate head office is in Sydney, and our operations extend to licensed manufacturing, warehousing, import/export, sales and distribution centers in the Gold Coast (Australia), Nagoya (Japan), Manchester (UK), and Prague (Czechia).

Our business model is focused on manufacture of final dose form / finished products, sales and distribution in each of the territories we serve. We work with raw materials and API suppliers in 5 continents and are a market leader in manufacturing scope and quality.

The BLS logo is derived from a Japanese Maple Leaf, symbolising health, happiness and a long life well lived. While the Japanese Maple is not a medicinal plant, our company purpose is to redefine medicine by taking a holistic approach to healthcare for a healthier and happier tomorrow.

Outside of Australia the BLS Group operates a health and wellness products and brands business focussed on naturally derived active nutraceuticals, wellness and lifestyle supplements and cannabidiol (CBD) based novel foods. It primarily operates in the UK, Europe and Japan, and engages in the following activities:

- (a) owner of Dr Watson® brand in the UK, Japan, Australia and New Zealand – Dr Watson is an internationally recognized health, lifestyle, and prescription products brand. Dr Watson products consist of cannabis-based food supplements, lifestyle products, cosmetics, functional mushrooms and nootropics, and prescription medicines in Australia;
- (b) contract manufacture and wholesale of raw materials and cannabinoid extracts in Japan, UK and Europe;
- (c) white label manufacture of third-party wellness and supplements brands in Japan, UK and Europe in company-owned facilities;
- (d) research and development for third party customers; and
- (e) direct sales via online and wholesale sales of BLS-owned consumer brands, such as Dr Watson® (drwatsoncbd.com, nolcbn.com, drwatsoncbd.de)

Corporate: <https://bioxyne.com>

Australia: <https://bls.com.au>; <https://blsclinics.com.au>

International: <https://breathelifesciences.com>

About Cy Biopharma AG

Founded in 2020 and based in Switzerland since 2021, Cy Biopharma AG is a privately held, international biopharma company. Globally, the team at Cy Biopharma is dedicated to unlocking the therapeutic power of 5HTx agonists. Led by CEO Dr Anton Hoos, Cy Biopharma prioritises innovation in pain and rare diseases, employing natural and novel 5HTx agonists to improve the lives of patients and their families.

In the EU, Cy Biopharma Ltd (Ireland) is actively developing new therapeutic options for orphan conditions. Cy Biopharma is planning clinical development activities for psilocybin and engineering next generation 5HTx agonism-based novel psychedelic molecules with the goal of delivering improved pharmacological profiles suited to our target indications.

In the US, Cy Biopharma Inc has been supporting an FDA-approved pilot trial in oncological pain via a philanthropic partnership. Initiated by Principal Investigator Dr Beaussant at the Harvard Dana-Farber Cancer Centre, the study seeks to examine the potential of psilocybin to treat opioid resistant pain. In South America, we are engaged in process research and manufacture to ensure professional cultivation of naturally derived serotonin receptor agonists. Cy Biopharma has been granted multiple import permits for psychedelics into the United States and Europe.

Today, Cy Biopharma is pleased to announce their collaboration with Bioxyne (BXN:ASX) subsidiary Breathe Life Sciences (BLS) in Australia. They are experienced distributors and the first and only licensed manufacturer of psilocybin in the country. BLS and Cy Biopharma are ideal partners in the region. Together, we will work in Australia and New Zealand so that government, clinical researchers, authorized prescribers, and patients can be assured of a reliable and safe supply of naturally-derived pharmaceutical quality psilocybin.